X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7481) 7481
Book Review (2345) 2345
Newspaper Article (1647) 1647
Newsletter (966) 966
Publication (687) 687
Trade Publication Article (104) 104
Book Chapter (71) 71
Magazine Article (52) 52
Book / eBook (38) 38
Transcript (34) 34
Conference Proceeding (23) 23
Web Resource (14) 14
Dissertation (6) 6
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5848) 5848
humans (5645) 5645
lymphomas (5113) 5113
oncology (3649) 3649
hematology (3043) 3043
cancer (2982) 2982
male (2359) 2359
female (2234) 2234
middle aged (2047) 2047
aged (1849) 1849
lymphoma (1760) 1760
care and treatment (1749) 1749
chemotherapy (1737) 1737
rituximab (1711) 1711
leukemia (1607) 1607
adult (1560) 1560
non-hodgkins-lymphoma (1458) 1458
research (1424) 1424
antineoplastic combined chemotherapy protocols - therapeutic use (1315) 1315
treatment outcome (1186) 1186
non-hodgkin's lymphomas (1172) 1172
mantle cell lymphoma (1158) 1158
chronic lymphocytic-leukemia (1156) 1156
antineoplastic agents - therapeutic use (1153) 1153
animals (1057) 1057
drug therapy (1048) 1048
apoptosis (1002) 1002
lymphoma, mantle-cell - drug therapy (988) 988
clinical trials (979) 979
b-cell lymphoma (969) 969
prognosis (843) 843
aged, 80 and over (796) 796
follicular lymphoma (740) 740
therapy (734) 734
health aspects (733) 733
patients (731) 731
hemic and lymphatic diseases (730) 730
transplantation (730) 730
cancer therapies (714) 714
medicine & public health (714) 714
analysis (691) 691
cell line, tumor (691) 691
multiple myeloma (691) 691
antineoplastic agents (681) 681
lymphoma, non-hodgkin - drug therapy (679) 679
medical research (671) 671
pharmaceutical industry (656) 656
antimitotic agents (654) 654
tumors (652) 652
stem cells (596) 596
antibodies, monoclonal - therapeutic use (592) 592
immunotherapy (585) 585
bortezomib (578) 578
lymphoma, mantle-cell - pathology (566) 566
survival (564) 564
antineoplastic agents - pharmacology (554) 554
antibodies, monoclonal, murine-derived (550) 550
disease-free survival (520) 520
mice (511) 511
pharmacology & pharmacy (501) 501
proteins (499) 499
expression (498) 498
genetic aspects (483) 483
immunology (475) 475
hematology, oncology and palliative medicine (473) 473
kinases (464) 464
phase-ii (451) 451
antineoplastic combined chemotherapy protocols - administration & dosage (450) 450
article (438) 438
fda approval (438) 438
apoptosis - drug effects (433) 433
drug dosages (432) 432
lymphoma, b-cell - drug therapy (430) 430
diagnosis (429) 429
immune system diseases (428) 428
recurrence (424) 424
reports (422) 422
retrospective studies (415) 415
multiple-myeloma (411) 411
gene expression (410) 410
cyclophosphamide - administration & dosage (406) 406
risk factors (402) 402
phase-ii trial (395) 395
abridged index medicus (390) 390
survival analysis (390) 390
non-hodgkin lymphoma (384) 384
antineoplastic combined chemotherapy protocols - adverse effects (382) 382
disease (381) 381
cyclophosphamide (380) 380
medicine, experimental (379) 379
development and progression (374) 374
t cells (369) 369
clinical trials as topic (368) 368
pathology (367) 367
medicine (365) 365
antineoplastic agents - adverse effects (360) 360
non-hodgkin's lymphoma (360) 360
anti-cd20 monoclonal-antibody (358) 358
mutation (357) 357
bone marrow (355) 355
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (18) 18
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Hospital Department (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10264) 10264
Japanese (36) 36
German (29) 29
French (22) 22
Chinese (13) 13
Spanish (10) 10
Russian (5) 5
Polish (4) 4
Dutch (3) 3
Hungarian (3) 3
Czech (2) 2
Catalan (1) 1
Hebrew (1) 1
Italian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 03/2015, Volume 372, Issue 10, pp. 944 - 953
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 6, pp. 507 - 516
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1835 - 1844
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3822 - 3829
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10020, pp. 770 - 778
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 13, pp. 1250 - 1260
The use of rituximab every 2 months for 3 years after immunochemotherapy and autologous stem-cell transplantation prolonged progression-free and overall... 
TRIAL | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | IMMUNOCHEMOTHERAPY | NORDIC MCL2 | FOLLOW-UP | HIGH-DOSE CYTARABINE | PHASE-3 | INTERGROUP | MCL YOUNGER | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Humans | Middle Aged | Immunologic Factors - administration & dosage | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Lymphoma, Mantle-Cell - drug therapy | Male | Transplantation, Autologous | Combined Modality Therapy | Cytarabine - administration & dosage | Cisplatin - administration & dosage | Lymphoma, Mantle-Cell - mortality | Rituximab - administration & dosage | Lymphoma, Mantle-Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Adult | Female | Aged | Maintenance Chemotherapy | Care and treatment | Usage | Patient outcomes | Mantle cell lymphoma | Stem cells | Outcome and process assessment (Health Care) | Reports | Transplantation | Observations | Medical research | Autografts | Dexamethasone | Cell survival | Hypersensitivity | Stem cell transplantation | Rituximab | Lymphoma | Cancer therapies | Survival | Studies | Chemotherapy | Cytarabine | Platinum | Lymphomas | Index Medicus | Abridged Index Medicus | Life Sciences | Hematology | Human health and pathology
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 6, pp. 520 - 531
This international prospective study showed that maintenance therapy with rituximab was more effective than interferon alfa in prolonging the duration of... 
FCM | MEDICINE, GENERAL & INTERNAL | THERAPY | PROSPECTIVE RANDOMIZED-TRIAL | CYCLOPHOSPHAMIDE | PROGRESSION-FREE SURVIVAL | RITUXIMAB | CHRONIC LYMPHOCYTIC-LEUKEMIA | COMBINATION | FLUDARABINE | STUDY-GROUP GLSG | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Aged, 80 and over | Female | Maintenance Chemotherapy | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Survival Rate | Vidarabine - analogs & derivatives | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Vidarabine - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Fludarabine | Mantle cell lymphoma | Aged patients | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Clinical trials | Prednisone | Lymphoma | Doxorubicin | Patients | Vincristine | α-Interferon | Cyclophosphamide | Motivation | Remission | Lymphomas | Computer centers | Age | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology | Index Medicus | Abridged Index Medicus
Journal Article